This inventor holds 1 USPTO granted patent. Top assignees: Cytel Corporation, Sloan-Kettering Institute for Cancer Research. Active years: 2000.
Company Filing History:
1 out of 34 
1 out of 518 
Years Active: 2000
Title: Monica Bocchia: Innovator in Cancer Vaccine Development
Introduction
Monica Bocchia is a prominent inventor based in New York, NY (US), known for her groundbreaking work in the field of cancer research. She has made significant contributions to the development of peptide vaccines targeting oncogene fusion proteins, particularly in relation to chronic myelogenous leukemia (CML). Her innovative approach has the potential to enhance cancer treatment and improve patient outcomes.
Latest Patents
Monica Bocchia holds a patent for "Oncogene fusion protein peptide vaccines." This patent focuses on fusion-point spanning peptides, such as BCR-ABL fusion breakpoint peptides associated with CML. These peptides bind to major histocompatibility complex molecules, including HLA class I molecules, and induce cytotoxic T cell proliferation. The breakthrough peptides can be utilized as effective vaccines in cancer therapy.
Career Highlights
Throughout her career, Monica has worked with esteemed organizations, including the Sloan-Kettering Institute for Cancer Research and Cytel Corporation. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in cancer research.
Collaborations
Monica Bocchia has collaborated with notable colleagues, including David A. Scheinberg and Alessandro D. Sette. These partnerships have further enriched her research and have played a crucial role in the development of her innovative vaccine strategies.
Conclusion
Monica Bocchia's contributions to cancer vaccine development exemplify her dedication to advancing medical science. Her innovative work in peptide vaccines holds promise for improving treatment options for patients with chronic myelogenous leukemia.